|4Feb 18, 5:00 PM ET

Buckbee Kevin K 4

4 · AbbVie Inc. · Filed Feb 18, 2025

Insider Transaction Report

Form 4
Period: 2025-02-13
Buckbee Kevin K
SVP, CONTROLLER
Transactions
  • Award

    Common Stock, $0.01 par value

    2025-02-13+3,59510,578 total
  • Award

    Common Stock, $0.01 par value

    2025-02-13+1,47412,052 total
  • Award

    Common Stock, $0.01 par value

    2025-02-13+1,60413,656 total
  • Award

    Common Stock, $0.01 par value

    2025-02-13+1,67415,330 total
  • Award

    Option (Right to buy)

    2025-02-13+6,2506,250 total
    Exercise: $192.86Exp: 2035-02-12Common Stock (6,250 underlying)
Footnotes (5)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,084 on February 13, 2026, 2,083 on February 13, 2027, and 2,083 on February 13, 2028.

Documents

1 file
  • 4
    form4-02182025_050220.xmlPrimary